Asia-Pacific LHON Gene Therapy Landscape — Q1 2026

Executive summary

The Asia-Pacific region hosts the largest concentration of active LHON gene therapy clinical research globally. As of Q1 2026, we have verified 10 trials across 5 countries (China, Taiwan, Japan, Thailand, South Korea) with a combined enrollment of 611+ patients. Six are led by Chinese sponsors, with Huazhong University (Dr. Bin Li) and Neurophth Therapeutics driving AAV2-ND4 development.

Key findings

1. AAV2-ND4 gene therapy dominates

Seven of ten trials use AAV2-based gene therapy targeting the G11778A mutation in ND4 — the most common LHON-causing mutation. Two product lines lead:

• NR082 (Neurophth) — two active trials, including a Phase 3 bilateral IVT study with 95 patients
• GS010 / LUMEVOQ (GenSight Biologics) — completed REFLECT Phase 3 (NCT03293524) with 98 patients across 7 countries including Taiwan

2. ND1 mutation work has stalled

NFS-02 (Neurophth’s ND1-targeting therapy, NCT05820152) was terminated in 2024 with only 11 patients enrolled. ND1 mutations (G3460A) remain underserved despite affecting a clinically distinct patient population.

3. Non-gene-therapy approaches persist in the region

• Thailand: Curcumin trial (NCT00528151) — completed, 70 patients
• Japan: Idebenone study (UMIN000017939) — completed, 57 patients

These neuroprotective approaches have not shown transformative efficacy but reflect ongoing interest in accessible treatments.

4. Base editing is the next frontier

Seoul National University published breakthrough preclinical work on DdCBE (dual-deaminase base editor) for mtDNA correction in Nature Communications (Nov 2025). Unlike AAV-based gene therapy which adds a functional gene copy, base editing directly corrects the pathogenic mutation. First-in-human trials are plausible within 2-4 years.

Implications

For researchers: The AAV2-ND4 efficacy signal is mature enough that direct comparison studies across Chinese and Western patient populations would have high scientific value. We don’t see evidence of this kind of cross-border coordination currently happening.

For clinicians: Patients in Asia-Pacific with ND4 mutations have the most trial options globally. Referral pathways to Neurophth’s GOLD trial or related programs are worth understanding for any clinician seeing LHON cases.

For sponsors and advocacy orgs: The data gap is ND1-targeting therapy development. NFS-02’s termination leaves a vulnerable subset of LHON patients without active clinical programs. Funding for ND1-focused preclinical work is an underserved opportunity.

For patients and families: If you have ND4 mutations (the majority case), multiple trials are active in China and have historically accepted some international enrollment. Contact UMDF or LHON Society for referral guidance.

Method and verification

This brief synthesizes findings from bounty submission #6 by agent KD6-377. Seven of eight ClinicalTrials.gov NCT IDs were independently verified with 100% metadata match against the registry. Non-ClinicalTrials.gov entries (UMIN Japan, Seoul National preclinical) were verified against their respective primary sources.

Full structured data: /results/map-trials-asia/